Russell C Callaghan1,2,3, Jodi M Gatley1,2,3, Jenna Sykes4, Lawren Taylor5. 1. Northern Medical Program, University of Northern British Columbia, Prince George, Canada. 2. Human Brain Laboratory, Centre for Addiction and Mental Health, Toronto, Canada. 3. Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. 4. Department of Biostatistics, Princess Margaret Cancer Centre (University Health Network), Toronto, Canada. 5. Work, Stress and Health Program, Centre for Addiction and Mental Health, Toronto, Canada.
Abstract
INTRODUCTION AND AIMS: Even though individuals with substance-use disorders have a high prevalence of tobacco smoking, surprisingly little is known about smoking-related mortality in these populations. The current retrospective cohort study aims to address this gap. DESIGN AND METHODS: The study sample included cohorts of individuals hospitalised in California between 1990 and 2005 with alcohol- (n = 509 422), cocaine- (n = 35 276), opioid- (n = 53 172), marijuana- (n = 15 995) or methamphetamine-use (n = 36 717) disorders. Death records were linked to inpatient data. Age-, race- and sex-adjusted standardised mortality ratios (SMR) were generated for 19 smoking-related causes of death. RESULTS: Smoking-related conditions comprised 49% (79 188/163 191) of total deaths in the alcohol, 40% (1412/3570) in the cocaine, 39% (4285/11 091) in the opioid, 42% (554/1332) in the methamphetamine and 36% (1122/3095) in the marijuana cohorts. The SMRs for all smoking-linked diseases were: alcohol, 3.57 (95% confidence interval [CI] = 3.55 to 3.58); cocaine, 2.40 (95% CI = 2.39 to 2.41); opioid, 4.26 (95% CI = 4.24 to 4.27); marijuana, 3.73 (95% CI = 3.71 to 3.74); and methamphetamine, 2.58 (95% CI = 2.57 to 2.59). The SMRs for almost all of the 19 cause-specific smoking-related outcomes were elevated across cohorts. DISCUSSION AND CONCLUSIONS: Given the current findings, addressing tobacco smoking among persons with substance-use disorders should be a critical concern, especially given the heavy smoking-related mortality burden and the currently limited attention devoted to smoking in these populations. [Callaghan RC, Gatley JM, Sykes J, Taylor L. The prominence of smoking-related mortality among individuals with alcohol- or drug-use disorders. Drug Alcohol Rev 2018;37:97-105].
INTRODUCTION AND AIMS: Even though individuals with substance-use disorders have a high prevalence of tobacco smoking, surprisingly little is known about smoking-related mortality in these populations. The current retrospective cohort study aims to address this gap. DESIGN AND METHODS: The study sample included cohorts of individuals hospitalised in California between 1990 and 2005 with alcohol- (n = 509 422), cocaine- (n = 35 276), opioid- (n = 53 172), marijuana- (n = 15 995) or methamphetamine-use (n = 36 717) disorders. Death records were linked to inpatient data. Age-, race- and sex-adjusted standardised mortality ratios (SMR) were generated for 19 smoking-related causes of death. RESULTS: Smoking-related conditions comprised 49% (79 188/163 191) of total deaths in the alcohol, 40% (1412/3570) in the cocaine, 39% (4285/11 091) in the opioid, 42% (554/1332) in the methamphetamine and 36% (1122/3095) in the marijuana cohorts. The SMRs for all smoking-linked diseases were: alcohol, 3.57 (95% confidence interval [CI] = 3.55 to 3.58); cocaine, 2.40 (95% CI = 2.39 to 2.41); opioid, 4.26 (95% CI = 4.24 to 4.27); marijuana, 3.73 (95% CI = 3.71 to 3.74); and methamphetamine, 2.58 (95% CI = 2.57 to 2.59). The SMRs for almost all of the 19 cause-specific smoking-related outcomes were elevated across cohorts. DISCUSSION AND CONCLUSIONS: Given the current findings, addressing tobacco smoking among persons with substance-use disorders should be a critical concern, especially given the heavy smoking-related mortality burden and the currently limited attention devoted to smoking in these populations. [Callaghan RC, Gatley JM, Sykes J, Taylor L. The prominence of smoking-related mortality among individuals with alcohol- or drug-use disorders. Drug Alcohol Rev 2018;37:97-105].
Authors: Noah R Gubner; Denise D Williams; Thao Le; Wayne Garcia; Maya Vijayaraghavan; Joseph Guydish Journal: Drug Alcohol Depend Date: 2019-02-05 Impact factor: 4.492
Authors: Alyssa M Medenblik; Patrick S Calhoun; Stephen A Maisto; Daniel R Kivlahan; Scott D Moore; Jean C Beckham; Sarah M Wilson; Dan V Blalock; Eric A Dedert Journal: Subst Abuse Date: 2021-09-16
Authors: Alba González-Roz; Roberto Secades-Villa; Gema Aonso-Diego; Sara Weidberg; José R Fernández-Hermida Journal: Psychopharmacology (Berl) Date: 2021-05-24 Impact factor: 4.530
Authors: Isabel Martinez Leal; Jayda Martinez; Maggie Britton; Tzuan A Chen; Virmarie Correa-Fernández; Bryce Kyburz; Vijay Nitturi; Ezemenari M Obasi; Kelli Drenner; Teresa Williams; Kathleen Casey; Brian J Carter; Lorraine R Reitzel Journal: Int J Environ Res Public Health Date: 2022-06-23 Impact factor: 4.614
Authors: Heather Palis; Kirsten Marchand; Mohammad Karamouzian; Scott MacDonald; Scott Harrison; Daphne Guh; Kurt Lock; Suzanne Brissette; Aslam H Anis; Michael Krausz; David C Marsh; Martin T Schechter; Eugenia Oviedo-Joekes Journal: Addict Behav Rep Date: 2018-03-27